Melanoma Trial, Recruiting NCT06967961 Sponsor: Institut Claudius Regaud Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT06967961
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with one of these specific cancer types: bladder/urinary tract cancer (urothelial carcinoma), kidney cancer, prostate cancer, cancers of the mouth/throat/upper airway area, cervical cancer, uterine (endometrial) cancer, skin melanoma, soft tissue sarcoma, or testicular germ cell tumors
  • People whose cancer has spread to other parts of the body (metastatic disease) and who have not yet started treatment for this stage of the disease
  • People aged 18 or older
  • People enrolled in the French Social Security system
  • People who have signed a consent form agreeing to take part before any study-related procedures begin

Who may not be able to join:

  • People whose cancer has not spread and remains in one localised area
  • People who are pregnant or currently breastfeeding
  • People whose personal, family, psychological, geographical, or social situation may make it difficult to follow the study's required procedures and appointments
  • People who are under legal guardianship, court protection, or whose personal freedoms are restricted by an administrative or legal order

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0033 5 31 15 51 70

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut Claudius Regaud
Registry
ClinicalTrials.gov
Start date
23 July 2025
Est. completion
23 July 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Rate of patients presenting blood circulating DP cells detected by at least one of the two tested techniques (Flow Cytometry/ CellSearch® or Parsortix® according to the type of tumor)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov